Title

精神分裂症患者代謝性症候群危險因子之相關性研究

Translated Titles

The Survey of the Risk Factors for Metabolic Syndrome in Schizophrenia

DOI

10.6832/KMU.2007.00075

Authors

鄭沁綺

Key Words

精神分裂症 ; 代謝性症候群 ; 抗精神病藥物 ; Apo E allele 基因型 ; schizophrenia ; metabolic syndrome ; antipsychotics ; Apo E allele

PublicationName

高雄醫學大學行為科學研究所學位論文

Volume or Term/Year and Month of Publication

2007年

Academic Degree Category

碩士

Advisor

龍佛衛

Content Language

繁體中文

Chinese Abstract

目的:近幾年來關於非典型抗精神病藥物使用後產生代謝性症候群的研究愈來愈多,及有關於基因如Apo E polymorphism與脂質相關在代謝性疾患扮演重要的角色。精神分裂症患者在使用傳統及非典型抗精神病藥物治療卻並不一定會罹患代謝性疾患。因此希望能藉由這個研究來確實了解抗精神病藥物與代謝性症候群在精神分裂症者的關係,以評估非典型抗精神病藥物長期治療的患者罹患代謝性症候群的可能性,進一步探討精神分裂症的Apo E allele 基因型在代謝性症候群與使用抗精神病藥物之間的關連。 方法:本研究採單中心,無對照組,回溯性病歷回顧之臨床研究模式。本研究將收集約111個南部某區域教學醫院精神科病患,納入本研究的標準為診斷符合DSM-III-R 精神分裂症及情感性精神分裂症。病患基本資料透過病歷回顧與臨床評估收集,包括年齡、發病年齡、性別、身高、體重,血壓、空腹血糖、膽固醇,三酸甘油脂、同時萃取DNA進行Apo E基因多型性鑑定,收集使用的抗精神病藥物種類。統計以多變量迴歸分析方法及結構方程模式 (AMOS) 來分析做比較因果關係。 結果:多變量迴歸分析方法及結構方程模式 (AMOS) 顯示,在非典型抗精神病藥物與得高血壓有負向直接影響 (β=-.18, p =0.049),同時與三酸甘油脂 (β=-.31, p<0.001) 及膽固醇 (β=-.21, p =0.026) 有負向直接影響,顯示非典型抗精神病藥物比較於傳統抗精神病藥物反而得高血壓及高血脂的情形較少。同時顯示非典型抗精神病藥物對身體質量指數 (BMI) 無直接影響而是間接的影響。 討論:本研究發現非典型抗精神病藥物比較於傳統抗精神病藥物反而得高血壓及高血脂的情形較少,尤其在三酸甘油脂的部份最明顯。另外非典型抗精神病藥物與身體質量指數並無直接的影響,而是經由三酸甘油脂及高血壓間接來影響身體質量指數。

English Abstract

Objective: The metabolic syndrome has been recognized as a side effect of antipsychotic treatment. ApoE polymorphism was associated with lipid metabolism in the metabolic syndrome. The study explored the relationship of schizophrenia and metabolic syndrome and predicted the prevalence about the risk of metabolic syndrome in the atypical antipsychotic treatment. Further, we explored the relationship between the ApoE genotypes and metabolic syndrome in schizophrenic patients. Method: This is a retrospective and chart review study. Total of 111 Taiwanese patients met the DSM III-R criteria for schizophrenia and schizoaffective disorder. All individuals were collected the data of age, onset age, gender, height, weight, blood pressure, fasting glucose, triglyceride, cholesterol level, ApoE genotype and the type of antipsychotics. Logistic regression and structural equation modeling were used to identify the relationship of cause and effect. Results: The logistic regression and structural equation modeling revealed that atypical antipsychotics negative directly influenced hypertension (β=-.18, p =0.049), triglyceride (β=-.31, p<0.001) and cholesterol (β=-.21, p =0.026) of plasma. The atypical antipsychotics compared with conventional antipsychotics individuals less hypertension and hyperlipidemia. In the study, the atypical antipsychotics showed indirect influence with the variable of body mass index. Conclusion: Our findings showed atypical antipsychotics compared with conventional antipsychotics individuals decreases risk of hypertension and hyperlipidemia, especially predominant on triglyceride plasma level. The atypical antipsychotic did not directly influenced body mass index (BMI), but indirectly influenced BMI by the variables of hypertension and triglyceride.

Topic Category 醫藥衛生 > 醫藥總論
健康科學院 > 行為科學研究所
社會科學 > 心理學
Reference
  1. 中文資料
  2. 顏永杰 ( 民89 ) 阿滋海默病與Apo E4 基因之相關性。高雄醫學大學行為科學研究所碩士論文。
  3. 英文資料
  4. Adiseshiah, M. (2005). Effective care of patients with type 2 diabetes and dyslipidemia. Diabetes Research and Clinical Practice,68, 23-27.
  5. Allison, D.B., Mentore, J.L., Heo, M.,et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156 (11), 1686-1696.
  6. American Diabetes Association, American Psychiatric Association, American Association of clinical Endocrinologist, North American Association for the Study of Obesity. (2004), Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. The Journal of Clinical Psychiatry, 65, 267-272.
  7. Ananth, J., Venkatesh, R., Burgoyne, K., Gadasalli, R., Binford, R., Gunatilake, S. (2004). Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry, 16(2), 75-85. Review.
  8. Anker, S.D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C.,et al. (2003). Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation, 107, 1991-1997.
  9. Basu, R., Bara, J.S., Chengappa, K.N.R., et al. (2004). The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disorder, 6, 314-318.
  10. Beasley, C.M. (1997). Safety of Olnazapine. The Journal of Clinical Psychiatry, 15 (2), 19-21.
  11. Bobes, J., Arango, C., Aranda, P., Carmena, R., Garcia-Garcia, M., Rejas, J., CLAMORS Study Collaborative Group. (2007). Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophrenia Research. 90(1-3), 162-173.
  12. Boston, P.F., Dursun, S.M., Reverley, M.A. (1996a). Cholestrol and mental disorder. British Journal of Psychiatry, 196, 682-689.
  13. Boston, P.F., Dursun, S.M., Zafar, R., Reverley, M.A. (1996b). Serum cholesterol and treatment resistance in schizophrenia. Biological Psychiatry, 40, 542-543.
  14. Bray, G..A. (1985). Complications of obesity. Annals of Internal Medicine, 103, 1052- 1062.
  15. Chan, J.M., Rimm, E.B., Colditz, G.A., Chan, J.M., Rimm, E.B., Coldita, G.A., Stampfer, M.J., Willett, W.C. (1994).Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care, 17(9), 961-969.
  16. Chen, J.Y., Hong ,C.J., Chiu, H.J., Lin, C.Y., Bai, Y.M., Song, H.L., Lai, H.C., Tsai, S.J. (1999). Apolipoprotein E genotype and Schizophrenia. Neuropsychobiology, 39(3), 141-143
  17. Chen, Y.C., Ku, C.S. (1993).Instruction manual for the Structured Clinical Interview for DSM-III-R (SCID), Chinese version Kaohsiung. 3rd ed. Kaohsiung, Taiwan: Kaohsiung Medical College.
  18. Cohn, T., Prud’homme, D., Streiner, D., Kameh, H., Remington, G.. (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry, 49, 753- 760.
  19. Colditz, G.A., Willett, W.C., Rotnitzky, A., Manson, J.E. (1995).Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine, 122, 481-486.
  20. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N.H., Eberlein, K.A., et al. (1990). Blood pressure, stroke and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet, 335, 827-838.
  21. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G..W., et al. (1993).Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261 (5123), 921-923.
  22. Dallongeville, J., Lussier-Cacan, S., Davigon, J. (1992). Modulation of plasma triglyceride levels by ApoE phenotype: a meta-analysis. Journal of Lipid Research, 33, 447-454.
  23. Emi, M., Wu, L.L., Robertson, M.A., et al. (1988).Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics, 3, 373-379.
  24. Eto, M., Watanabe, K., Ishi, K. (1986). Reciprocal effects of apilipoprotein E alleles (e2 and e4) on plasma lipid levels in normolipidemic subjects. Clinical Genetics, 29, 477-484.
  25. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). The Journal of the American Medical Association, 285, 2486- 2497.
  26. Fontaine, K.R., Heo, M., Harrigan, E.P., Shear, C.L., Lakshminarayanan, M., Casey, D.E., Allison, D.B. ( 2001). rdEstimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research, 101, 277-288.
  27. Gelber, R.P., Gaziano, J.M., Manson, J.E., Buring, J.E., Sesso, H.D. (2007).A prospective study of body mass index and the risk of developing hypertension in men. American Journal of Hypertension, 20(4), 370-377.
  28. Ghaeli, P., Dufresne, R.L. (1996). Serum triglyceride levels in patients treated with Clozapine. American Journal of Health-System Pharmacy, 53, 2079-2081.
  29. Hagg, S., Joelsson, L., Mjorndal, T., Spigset, O., Oja, G., Dahlqvist, R.( 1998). Prevalence of diabetes and impaired glucose tolerance in patients treated with conventional depot neuroleptic medications. The Journal of Clinical Psychiatry, 59, 294-299.
  30. Hardy, T.A., Marquez, E.. Kryzhanovskaya, L.. Taylor, C.C., Cavazzoni, P. (2006). Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. Journal of Clinical Psychopharmacology, 26(4), 405-408.
  31. Harrington, C.R., Roth, M., Xuereb, J.H., McKenna, P.J., Wischik, C.M. (1995). Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neuroscience Letters, 202, 101-104.
  32. Hebert, P.R., Fiebach, N.H., Eberlein, K.A., et al. (1988). The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. American Journal of Epidemiology, 127, 581-590.
  33. Heiskanen, T., Niskanen, L., Lyytikainen, R., Saarinen, P.I., Hintikka, J. (2003). Metabolic syndrome in patients with schizophrenia. The Journal of Clinical Psychiatry, 64, 575-579.
  34. Henderson, D.C., Daley, T.B., Kunkel, L., Rodrigues-Scott, M., Koul, P., Hayden, D., (2004). Clozapine and hypertension: a chart review of 82 patients. The Journal of Clinical Psychiatry, 65(5), 686-689.
  35. Hennekens, C.H., Hennekens, A.R., Holla, D., Casey, D.E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150(6), 1115-1121. Review.
  36. Hixon, J.E., Vemier, D.T. (1990). Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. Journal of Lipid Research, 31, 545-548.
  37. Hong, C.J., Yu Younger, W.Y., Lin, C.H., Song, H.L., Lai, H.C., Yang, K.H., et al. (2000). Association Study of Apolipoprotein Eε4 with Clinical Phenotype and Clozapine Response in Schizophrenia. Neuropsychobiology, 43, 172-174.
  38. Hu, G., Barengo, N.C., Tuomilehto, J., Lakka, T.A., Nissinen, A., Jousilahti, P. (2004). Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension, 43, 25-30.
  39. Huang, T.L., Wu, S.C. (2000). Serum cholesterol levels in paranoid and nonparanoid schizophrenia associated with physical violence or suicidal attempts in Taiwanese. Psychiatric Research, 96, 175-178.
  40. Huang, T.L. (2001). Serum cholesterol levels in affective disorders associated with physical violence or suicidal attempts in Taiwanese. Chang Gung Medical Journal, 24, 563-568.
  41. Huang, T.L., Chen, J.F. (2005) Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research, 80(1), 55-59.
  42. Kawachi, I. (1999). Physical and psychological consequences of weight gain. The Journal of Clinical Psychiatry, 60 suppl. 21, 5-9.
  43. Katsuya, T., Baba, S., Ishikawa, K., Mannami, T., Fu, Y., Inamotom, N., et al. (2002). Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. Journal of Hypertension, 20(10), 2017-2021.
  44. Keltner, N.L. (2006) Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspectives in Psychiatry Care, 42(3), 204-207.
  45. Kimura, T., Shono, M., Yokota, S., Igata-Yi, R., Takamatsu, J., Miyakawa, T. (2000). Apolipoprotein E epsilon3 allele is not a risk factor of schizophrenia: a study of 314 Japanese patients. Neuropsychobiology, 42(2), 66-68.
  46. Kunugi, H., Nanko, S., Ueki, A., Isse, K., Hirasawa, H. (1998). DLST gene and Alzheimer’s disease. Lancet, 351, 1584-1585.
  47. Lamberti, J.S., Bellnier, R., Schwarzkopf, S.B. (1992).Weight gain among schizophrenic patients treated with Clozapine. American Journal of Psychiatry, 149 (5), 689-690.
  48. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O. et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 22, 353(12), 1209-23.
  49. Lund, B.C., Perry, P.J., Brooks, J.M., Arndt. S. (2001). Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of General Psychiatry, 58 (12), 1172-1176.
  50. Lung, F.W., Kao, W.T., Shu, B.C., Yen, Y.C., Tzang, D.S. (2006). A module Map Showing Interaction between Apolipoprotein E and Phospholipase A2 Polymorphism in Lipid Profiles. Human Heredity, 62(3), 135-144.
  51. Lung, F.W., Yen, Y.C., Chou, L.J., Hong, C.J., Wu, C.K. (2005). The allele interaction between apolipoprotein epsilon2 and epsilon4 in Taiwanese Alzheimer's disease patients. Acta psychiatrica Scandinavica, 111(1), 38-43.
  52. Mahley, R.W. (1988).Apolipoprotein E: cholesterol transport protein with an expanding role in cell biology. Science, 240, 622-630.
  53. Masand, P.S. (1999a). Introduction. Weight gain with psychotropics: size does matter. The Journal of Clinical Psychiatry, 60 Suppl 21,3-4.
  54. Masand, P.S. (1999b). Relative weight gain among antipsychotics. The Journal of Clinical Psychiatry, 60, 706-708.
  55. Masand, P.S. (2000).Weight gain associated with psychotropic drugs.
  56. Expert Opinion on Pharmacotherapy, 1(3), 377-389. Review.
  57. McCreadie, R.G.., Scottish Schizophrenia Lifestyle Group. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.
  58. British Journal of Psychiatry, 183, 534-539.
  59. McKee, H.A., D’Arey, P.F., Wilson, P.J.K. (1986). Diabetes and schizophrenia-a preliminary study. Journal of Clinical and Hospital Pharmacy, 11, 297-299.
  60. Meyer, J.M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. The Journal of Clinical Psychiatry, 62, 27-34; discussion 40-41.
  61. Meyer, J.M., Koro, C.E. (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research, 70 (1), 1-17.
  62. Miller, D.C., Tmlson, M.E. McCann, M.B. et al. (1958). Diet, blood lipids and health of Italian men in Boston. Annals of Internal Medicine. 49, 1178-1200.
  63. Morgan, K., Lam, L., Kalsheker, N. (1996). A rapid and efficient method for DNA extraction from paraffin wax embedded tissue for PCR amplification. Clinical Molecular Pathology, 49, 179-180.
  64. Mukherjee, S., Decina, P., Bocola, V., et al. (1996). Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68-73.
  65. Ollendorf, D.A., Joyce, A.T., Rucker, M. (2004). Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Medscape General Medicine, 6(1), 5.
  66. Osser, D.N., Najarian, D.M., Dufresne, R.L. (1999).Olanzapine increases weight and serum triglyceride levels. The Journal of Clinical Psychiatry, 60 (11), 767-770.
  67. Poirier, J. (1994). Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends in Neurosciences, 17, 525-530.
  68. Popli, A.P., Konicki, P.E., Jurjus, G.J., et al. (1997). Clozapine associated with diabetes mellitus. The Journal of Clinical Psychiatry, 58, 108-11.
  69. Redelmeier, D.A., Siew, H.T., Booth, G.L. (1998). The treatment of unrelated disorders in patients with chronic medical disease. The New England Journal of Medicine, 338, 1516-1520.
  70. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (1988). The Expert Panel Archives of Internal Medicine, 48, 36-69.
  71. Reznik, Y., Morello, R., Pousse, P., Mahoudeau, J., Fradin, S. (2002). The effect of age, body mass index, and fasting triglyceride level on postprandial lipemia is dependent on apolipoprotein E polymorphism in subjects with non-insulin-dependent diabetes mellitus. Metabolism, 51(9), 1088-1092.
  72. Ruano, G., Goethe, J.W., Caley, C., Woolley, S., Holford, T.R., Kocherla, M., Windemuth, A., de Leon, J. (2007). Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Molecular Psychiatry,12(5), 474-482.
  73. Rubinsztein, D.C., Easton, D.F. (1999). Apolipoprotein E genetic variation and Alzheimer’s disease: a meta-analysis. Dementia and Geriatric Cognitive Disorders, 10, 199-209.
  74. Russell, J.M., Mackell, J.A. (2001). Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. [Review] CNS Drugs, 15(7), 537-551.
  75. Ryan, M.C., Collins, P., Thakore, J.H. (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry, 160(2), 284-289.
  76. Saito, M., Eto, M., Nitta, H., Kanda, Y., Shigeto, M., Nakayama, K., et al. (2004). Effect of Apolipoprotein E4 Allele on Plasma LDL Cholesterol Response to Diet Therapy in Type 2 Diabetic Patients. Diabetes Care, 27(6), 1276-1280
  77. Santar, N., Gaw, A., Scherbakova, O., et al. (2003). Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation, 108, 414–419.
  78. Spivak, B., Roitman, S., Vered, Y., et al. (1998). Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neurileptic-resisrant schizophrenic patients maintained on Clozapine. Clinical Neuropharmacology, 21, 245-250.
  79. Strous, R.D., Kupchik, M., Roitman, S., Schwartz, S., Gonen, N., Mester, R., Weizman, A., Spivak, B. (2006). Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Human Psychopharmacology, 21(4), 235-243.
  80. Sussanman, N., Ginsberg, D. (1999). Effects of psychotic drugs on weight. Psychiatric Annals, 29 (10), 580.
  81. Tsunoda, K., Harihara, S., Dashyam, B., Semjidmaa, D., Yamaguchi, Y., Tanabe, Y., et al. (2002). Apolipoprotein E and H polymorphism in Monogolian Byrant: allele frequencies and relationship with plasma lipid levels. Human Biology, 74, 659-671.
  82. Umbricht, D.S., Pollack, S., Kane, J.M. (1994). Clozapine and weight gain. The Journal of Clinical Psychiatry, 55, 157-160.
  83. Vierhapper, H., Nardi, A., Grosser, P. (2000). Prevalence of paradoxically normal serum cholestrol in morbidly obese women. Metabolism: Clinical & Experimental, 49(5),607-610.
  84. Wenham, P.R., Price, P.H., Blundell, A. (1991). Apolipoprotein E genotyping by one gate PCR. Lancet, 337, 1158-1159.
  85. Weisgraber, K.H. (1994). Apolipoprotein E: structure-function relationship. Advances in Protein Chemistry, 45, 249-302.
  86. Wirshing, D.A., Meyer, J.M. (2003). Obesity in patients with schizophrenia. In: Meyer JM, Narsrallah H, ed. Medical Illness and schizophrenia. Washington, DC: American Psychiatric Press, Inc.,39-58.
  87. World Health Organization. (1999). Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation.
  88. Yen, Y.C., Shu, B.C., Wang, C.S., Yang, M.J., Kao, W.T., Yang, M.J., Shih, C.H., Lung, F.W. (2006). A positive relationship between Apo ε2 allele and high-density lipoprotein cholesterol. Nutrition Research, 26, 443-449.
  89. Zaman, M.M., Ikemoto, S., Yoshiike, N., Date, C., Yokoyama, T., Tanaka, H. (1997). Association of apolipoprotein genetic polymorphisms with plasma cholesterol in Japan rural population: the Shibata Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 3495-3504.
  90. Zannis, V.I., Breslow, J.L., Utermann, G., Mahley, R.W., Weisgraber, K.H., Havel, R.J., et al. (1982).Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. Journal of Lipid Research, 23(6), 911-914.
  91. Zhang, J.G., MA, Y.X., Wang, C.F., et al. (1998).Apolipoprotein E and longevity among Ham Chinese Population. Mechanisms of Ageing & Development, 104, 159-167.
  92. Zolar, M..L. (1999). Antipsychotics linked to weight gain, diabetes. The Journal of Clinical Psychiatry News, 27 (2), 20.
Times Cited
  1. 孟繁莉(2010)。慢性精神分裂症患者健康生活型態之探討。中國醫藥大學護理學系碩士班學位論文。2010。1-132。 
  2. 魏婉菁(2010)。精神分裂症患者發生併發症及醫療耗用趨勢分析。中國醫藥大學環境醫學研究所碩士班學位論文。2010。1-111。